Cnbx Pharmaceuticals INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OID
CNBX Pharmaceuticals Inc. reported no revenue for the fiscal year ended August 31, 2025, with a net loss of $313,976, and auditors expressing substantial doubt about its ability to continue as a going concern.
OID
CNBX Pharmaceuticals Inc., a clinical-stage company, released its annual report, highlighting its focus on developing cannabinoid-based cancer treatments and its plans for upcoming clinical trials.